Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by Bayer
Hamilton Health Sciences Corporation, Population Health Research Institute
Information provided by (Responsible Party):
Bayer Identifier:
First received: January 24, 2013
Last updated: October 17, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2018
  Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)